Novartis Pharmaceuticals v. Watson Laboratories, Inc., No. 14-1799 (Fed. Cir. May 21, 2015)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Watson Laboratories, Inc., Watson Pharma , Inc., and Actavis, Inc. (collectively, “Watson”) appeal from the decision of the United States District Court for the Di s- trict of Delaware finding the asserted claims of U.S. Patents 6,316,023 (“the ’023 patent”) and 6,335,031 (“the ’031 patent”) not inval id as obvious. Novartis Pharm. Corp. v. Par Pharm., Inc. , 48 F. Supp. 3d 733 (D. Del. June 18, 2014) (“ Watson Trial Opinion ”); 2014-1799, 2014-1800 Joint Appendix (“J.A.1”) 1–4 (final judgment). NOVARTIS PHARMACEUTICALS v.